Prognostic value of the human kallikrein gene 15 expression in ovarian cancer

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3119-3126

  Yousef, George M ^a   Scorilas, Andreas ^a   Katsaros, Dionyssios ^a   Fracchioli, Stefano ^a   Iskander, Lisa ^a   Borgono, Carla ^a   Rigault de la Longrais, Irene A ^a   Puopolo, Manuela ^a   Massobrio, Marco ^a   Diamandis, Eleftherios P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 15; TUMOR MARKER; UNCLASSIFIED DRUG; CA 125 ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT; AGED; GENETICS; MIDDLE AGED; SURVIVAL;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; GENE EXPRESSION; HUMANS; KALLIKREINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 0041411417     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.111     Document Type: Article

References (43)

1. Niloff JM, Klug TL, Schaetzl E, et al: Elevation of serum CA-125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 148:1057-1058, 1984
2. Meyer T, Rustin GJ: Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer 82:1535-1538, 2000
3. Lambert-Messerlian GM: Is inhibin a serum marker for ovarian cancer? Eur J Endocrinol 142:331-333, 2000
4. Mok SC, Chao J, Skates S, et al: Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. J Natl Cancer Inst 93:1458-1464, 2001
5. Menon U, Jacobs IJ: Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 12:39-42, 2000
6. Welsh JB, Zarrinkar PP, Sapinoso LM, et al: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98:1176-11781, 2001
7. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 22:184-204, 2001
8. Yousef GM, Diamandis EP: Human kallikreins: Common structural features, sequence analysis and evolution. Curr Genomics 4:147-165, 2003
9. Yousef GM, Chang A, Scorilas A, et al: Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 276:125-133, 2000
10. Underwood LJ, Tanimoto H, Wang Y, et al: Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 59:4435-4439, 1999
11. Magklara A, Scorilas A, Katsaros D, et al: The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 7:806-811, 2001
12. Tanimoto H, Underwood LJ, Shigemasa K, et al: The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 86:2074-2082, 1999
13. Obiezu CV, Scorilas A, Katsaros D, et al: Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7:2380-2386, 2001
14. Kim H, Scorilas A, Katsaros D, et al: Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84:643-650, 2001
15. Dong Y, Kaushal A, Bui L, et al: Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 7:2363-2371, 2001
16. Yousef GM, Kyriakopoulou LG, Scorilas A, et al: Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker. Cancer Res 61:7811-7818, 2001
17. Diamandis EP, Yousef GM, Soosaipillai AR, et al: Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 33:579-583, 2000
18. Diamandis EP, Yousef GM, Soosaipillai AR, et al: Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 33:369-375, 2000
19. Luo L, Bunting P, Scorilas A, et al: Human kallikrein 10: A novel tumor marker for ovarian carcinoma? Clin Chim Acta 306:111-118, 2001
20. Yousef GM, Scorilas A, Jung K, et al: Molecular cloning of the human kallikrein 15 gene (KLK15): Up-regulation in prostate cancer. J Biol Chem 276:53-61, 2001
21. Takayama TK, Carter CA, Deng T: Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 40:1679-1687, 2001
22. Diamandis EP, Yousef GM, Luo LY, et al: The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab 11:54-60, 2000
23. Diamandis EP, Yousef GM: Human tissue kallikrein gene family: A rich source of novel disease biomarkers. Expert Rev Mol Diagn 1:182-190, 2001
24. Serov SF, Sorbin LH: Histological Typing of Ovarian Tumors. Geneva, Switzerland, World Health Organization, 1973
25. Pettersson F: Annual Report on the Treatment in Gynecological Cancer. Stockholm, Sweden, International Federation of Gynecology and Obstetrics, 1994
26. Day TG Jr, Gallager HS, Rutledge FN: Epithelial carcinoma of the ovary: Prognostic importance of histologic grade. Natl Cancer Inst Monogr 42:15-21, 1975
27. Bieche I, Onody P, Laurendeau I, et al: Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 45:1148-1156, 1999
28. Cox DR: Regression models and life tables. J R Slat Soc B 34:187-202, 1972
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
31. Luo LY, Katsaros D, Scorilas A, et al: Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7:2372-2379, 2001
32. Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90:1774-1786, 1998
33. Levine DA, Boyd J: The androgen receptor and genetic susceptibility to ovarian cancer: Results from a case series. Cancer Res 61:908-911, 2001
34. Silva EG, Tornos C, Fritsche HA Jr, et al: The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: A potential animal model. Mod Pathol 10:879-883, 1997
35. Helzlsouer KJ, Alberg AJ, Gordon GB, et al: Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274:1926-1930, 1995
36. Chadha S, Rao BR, Slotman BJ, et al: An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol 24:90-95, 1993
37. Kuhnel R, de Graaff J, Rao BR, et al: Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem 26:393-397, 1987
38. Slotman BJ, Rao BR: Response to inhibition of androgen action of human ovarian cancer cells in vitro. Cancer Lett 45:213-220, 1989
39. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
40. Zhang Z, Barnhill SD, Zhang H, et al: Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 73:56-61, 1999
41. Woolas RP, Xu FJ, Jacobs IJ, et al: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85:1748-1751, 1993
42. Khan J, Wei JS, Ringner M, et al: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673-679, 2001
43. de la Cuesta R, Maestro ML, Solana J, et al: Tissue quantification of CA 125 in epithelial ovarian cancer. Int J Biol Markers 14:106-114, 1999